In neurology, Lusofarmaco presents an innovative molecule belonging to triptans' class; by virtue of some unique features, this drug is proposed as a reliable treatment for the control of migraines, particularly effective with relapsing episodes. In this area, Lusofarmaco's commitment is synonymous of continuity in tradition. Since 1956 – with the launch of one of the first drugs used for the treatment of schizophrenia, and subsequently of another molecule that is still today a reference drug for the antipsychotic class of medications, thus confirming at the beginning of the new millennium its undiscussed leadership in this sector of pharmaceutical industry – the list of products has gradually increased in number due to the inclusion of numerous molecules that not only guarantee coverage of many therapeutic areas, but also represent a true turning point in the pharmacological approach to the treatment of neuropsychiatric disorders.

Brand Active Ingredient ATC Pack Reimbuersement Status
AURADOL Frovatriptan Triptan 2 tablets 2,5 mg Class: A
6 tablets 2,5 mg Class: A
FLUOXEREN Fluoxetine Antidepressant 60 ml oral solution 20 mg/5 ml Class: A
28 capsules 20 mg Class: A
28 tablets solubili 20 mg Class: A
ITALEPT  Levetiracetam  Antiepileptic 60 tablets 500 mg Class: A
30 tablets 1.000 mg Class: A
 300 ml Oral Solution 100mg/ml Class: A
ROLDAP Rasagiline Antiparkinson 28 Tablets 1 mg Classe: A*
SERENASE Aloperidol Antipsychotics 20 tablets 1 mg Class: C
drops 2 mg/ml 0,2% 15 ml Class: C
20 tablets 5 mg Class: A
drops 10 mg/ml 1% 15 ml Class: A

*Prescription subject to diagnosis and therapeutic plan drawn up by neurological centers

Our products

Lusofarmaco can claim extensive know-how in various therapeutic areas: cardiovascular and respiratory diseases, antibiotic therapy, neuropsychiatry and gynecology.

Research & Development

For many years, Lusofarmaco has been mainly a national company, with a portfolio focused on well-established medicinal products, which have been the reference drugs in their respective therapeutic areas.


The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem.

Registered Office:
Milanofiori – Strada 6, Edificio L – 20089 Rozzano (MI)
Tel. 02-516555.1 - Fax 02-516555.249

Registration No. In Registrar Of Companies: 00714810157
Registrar Of Companies' Office: Milano
Registered Capital: € 130.000 I.V.
Capital Reported In Last Financial Statement: € 130.000
Company subject to the direction and coordination of A. Menarini Industrie Farmaceutiche Riunite Srl


Copyright 2021 Istituto Lusofarmaco D'Italia S.p.A.